US Stock MarketDetailed Quotes
VSTM Verastem
- 4.5700
- +0.5200+12.84%
Close Nov 27 16:00 ET
- 4.6600
- +0.0900+1.97%
Post 20:01 ET
203.39MMarket Cap-1455P/E (TTM)
4.7700High4.0800Low2.80MVolume4.1100Open4.0500Pre Close12.62MTurnover9.22%Turnover RatioLossP/E (Static)44.51MShares14.220052wk High18.35P/B138.83MFloat Cap2.100052wk Low--Dividend TTM30.38MShs Float225.8400Historical High--Div YieldTTM17.04%Amplitude2.1000Historical Low4.5040Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Verastem Stock Forum
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...
No comment yet